ITN0127AI Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (AbATE) Follow-Up Study [EXTENSION OF 700008980]
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Teplizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 17 May 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov record.